Treatment-related toxicity from prior therapy > grade 2
Persisting toxicity related to prior therapy (NCI CTCAE v4.03 Grade > 1)
Subject has any Grade ? 2 persistent non-hematological toxicity related to allotransplant
Participants must have fully recovered (grade =< 1 or baseline or deemed irreversible) from any clinically significant acute toxicity related to prior therapy (with the exception of lymphopenia, which is common after therapy with temozolomide); patients who discontinued bevacizumab previously due to a bevacizumab-related toxicity will not be allowed to participate
Failure to recover from any immune-related toxicity from prior cancer therapy to ? Grade 1.
Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ? Grade 2.
Toxicity related to any prior therapy must either have returned to =< grade 1 or baseline
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baseline
Patient with any active immune toxicity of Grade 1 or greater or any other severe or Grade 3 treatment-related adverse event.
At least 4 weeks after any prior chemoembolization, radioembolization, local ablative therapies, or hepatic radiation and recovery to =< grade 1 treatment-related toxicity
At least 6 weeks after any major surgery including prior hepatic resection and recovery to =< grade 1 treatment-related toxicity
Persisting toxicity related to prior therapy >Grade 1
Toxicity related to prior treatments must either have resolved to grade 1 or less, returned to baseline, or be deemed irreversible
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baseline
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baseline
To be eligible for study treatment, radiation therapy-related toxicity must recover to Grade ? 1 prior to administration of the first dose of ARQ 751.
Recovered (returned to ? grade 1 as per CTCAE v4.03) from prior treatment-related toxicity.
Toxicity related to prior therapy must either have returned to =< grade 3, baseline, or deemed irreversible
Non-hematological toxicity related to prior therapy must either have returned to =< grade 3, baseline, or deemed irreversible
Toxicity from previous treatment including: a) Toxicity Grade >=3 related to prior immunotherapy and that lead to study treatment discontinuation. b) Toxicity related to prior treatment has not resolved to Grade <=1 (except alopecia, or endocrinopathy managed with replacement therapy).
Persisting toxicity related to prior therapy Grade >1.
Prior Grade 3 or higher immune-related AEs or any ocular toxicity on prior immunotherapy as per protocol-defined criteria.
Severe immune-related toxicity related to checkpoint inhibitors defined as any Grade 4 toxicity or Grade 3 toxicity
Severe immune-related toxicity related to checkpoint inhibitors defined as any Grade 4 toxicity or Grade 3 toxicity
Toxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversible
Toxicity related to prior therapy must either have returned to less than or equal to grade 1, baseline, or been deemed irreversible
Any Grade ? 2 persistent non-hematological toxicity related to allotransplant
Resolution of all chemotherapy related grade III-IV toxicity
History of significant intolerance to capecitabine or fluorouracil (5FU) (ie. grade 4 toxicity related to one of these agents; grade 3-4 toxicity related to other concurrently administered agents is not an exclusion)
Persisting toxicity related to prior therapy except alopecia
Grade 3 or 4 toxicity related to prior VEGFR TKI that did not resolve to grade 1
Toxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversible. Certain non-serious exceptions include alopecia, hypothyroidism, neuropathy, nausea, adrenocortical deficiency requiring physiologic replacement dose of steroids, and other conditions noted and approved by the principal investigator (PI).
Toxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversible. Certain non-serious exceptions include alopecia, hypothyroidism, neuropathy, nausea, adrenocortical deficiency requiring physiologic replacement dose of steroids, and other conditions noted and approved by the PI.
Patients are not eligible if they have an intolerance to most recent prior TKI (other than dasatinib) at the lowest possible effective dose, defined as a grade >= 3 toxicity considered at least possibly related to that TKI; patients are also excluded if they are intolerant or allergic to dasatinib and discontinued prior therapy due to a >= grade 2 treatment related adverse event
Recovery from acute toxicity related to prior therapy, including surgery and radiation, or no toxicity >= grade 2
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1
Toxicities related to prior therapy must either have returned to =< grade 1, baseline, or deemed irreversible
Toxicities related to prior therapy must either have returned to =< grade 1, baseline or deemed irreversible
Inadequate recovery from any toxicity related to prior treatment (to grade 2 or baseline)
Persisting toxicity related to prior therapy >Grade 1
Recovery from acute toxicity related to prior therapy, including surgery and radiation, or no toxicity >= grade 2
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baseline
Grade > 2 treatment-related toxicity from prior therapy
Toxicities related to prior therapy must either have returned to =< grade 1 or baseline or been deemed irreversible and in the opinion of the investigator not worsened
Resolution of all chemotherapy related grade III-IV toxicity as per Common Toxicity Criteria (CTC) criteria 4.0
Resolution of all chemotherapy related grade III-IV toxicity as per CTC criteria 4.0
PRIOR TO HIGH-DOSE CHEMOTHERAPY: Patients without evidence of ongoing grade III-IV toxicity related to mobilization therapy
Grade > 2 treatment-related toxicity from prior therapy
Grade > 2 treatment-related toxicity from prior therapy
Treatment related residual toxicity > grade 1
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baseline
Patients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baseline
Resolution of all chemotherapy related grade III-IV toxicity as per Common Toxicity Criteria (CTC) criteria 4.0
Resolution of all chemotherapy related grade III-IV toxicity as per CTC criteria 4.0
